stockrow
Friday 6 November 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- Revenue
- +12.5%
- EPS
- +84.6%
- Free cash flow
- +237.7%
- Total debt
- −5.97%
Quarter to September 2026, against a year earlier
2.17
0.26
−10.70%
Follow STIM
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.13 | 0.61 | 0.67 | 0.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
145.55 | (94.31) | (10.71) | 100.23 | |
P/B ratio |
8.04 | 4.39 | 5.91 | 3.47 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.42 | 0.94 | 1.03 | 0.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(27.46) | (14.07) | (12.23) | (6.68) | |
EV/FCF |
(24.72) | (12.92) | (11.55) | (6.43) | |
Quick Ratio |
1.05 | 1.46 | 1.25 | 1.68 | |
Current Ratio |
2.01 | 1.88 | 1.67 | 2.02 | |
Net Debt/EBITDA |
26.22 | (47.07) | (5.10) | (7.35) | |
Debt/Assets |
46.80% | 46.77% | 48.87% | 46.49% | |
Debt/Equity |
2.76 | 2.84 | 3.59 | 2.51 | |
Asset Turnover |
1.15 | 1.17 | 1.13 | 1.06 | |
Operating CF/Net income |
(0.73) | 0.29 | 0.87 | (0.13) | |
Capex/Depreciation |
0.00 | (0.57) | (0.23) | (0.28) | |
Interest Coverage |
0.25 | (0.71) | (3.97) | (2.18) | |
Research and Development Expense of Revenue |
2.84% | 3.21% | 3.96% | 3.99% | |
Selling, General and Administrative Expense of Revenue |
48.04% | 51.45% | 69.03% | 60.04% | |
Intangible Assets out of Total Assets |
0.31 | 0.31 | 0.33 | 0.30 | |
Share Based Compensation of Revenue |
0.42% | 1.66% | 4.87% | 5.22% | |
Graham Net Nets |
(0.31) | (0.60) | (0.61) | (0.59) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.10%) | (33.85%) | (37.24%) | (42.75%) | |
Free Cash Flow Yield |
(5.11%) | (11.81%) | (13.43%) | (23.27%) | |
Revenue per Share |
0.54 | 0.57 | 0.50 | 0.63 | |
Operating CF per Share |
0.02 | (0.01) | (0.14) | 0.01 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | (0.02) | (0.14) | 0.01 | |
Cash per Share |
0.37 | 0.34 | 0.28 | 0.52 | |
Shareholders Equity per Share |
0.29 | 0.30 | 0.25 | 0.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.29 | 0.30 | 0.25 | 0.40 | |
Free Cash Flow |
1.24 | (1.42) | (9.59) | 0.69 | |
Working Capital |
27.03 | 24.92 | 18.89 | 31.03 | |
Capital Expenditures |
— | (0.42) | (0.17) | (0.22) | |
Net Current Asset Value |
(55.67) | (56.66) | (61.20) | (53.76) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 21.46 | 21.55 | 20.59 | |
Average Payables |
10.77 | 11.07 | 9.96 | 10.91 | |
Average Inventory |
4.63 | 5.22 | 4.39 | 4.29 | |
Average Assets |
138.71 | 133.09 | 133.71 | 141.23 | |
Average Common Equity |
26.88 | 26.57 | 28.30 | 29.02 |
Columns are period end dates · fundamentals updated 4 Nov 2026